Company / Accounts Receivable
Seres Therapeutics, Inc. Accounts Receivable History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$157.0K
FY2025
5-year range
$157.0K / $9.4M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2M to $157,000 over the past 6 years.
Based on SEC 10-K filings.
$157,000 in FY2025.
Declined from $2M to $157,000 over the past 6 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -55.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -55.9%, indicating a declining trend.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $157.0K | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $9.4M | +425.9% |
| FY2019 | $1.8M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026